2018
Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy
Cui D, Peng Y, Zhang C, Li Z, Su Y, Qi Y, Xing M, Li J, Kim GE, Su KN, Xu J, Wang M, Ding W, Piecychna M, Leng L, Hirasawa M, Jiang K, Young L, Xu Y, Qi D, Bucala R. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. Journal Of Clinical Investigation 2018, 128: 4997-5007. PMID: 30295645, PMCID: PMC6205380, DOI: 10.1172/jci93090.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorAtypical antipsychotic therapyMIF expressionMigration inhibitory factorInsulin resistanceAntipsychotic therapyAtypical antipsychoticsMetabolic dysfunctionOlanzapine-induced insulin resistanceInhibitory factorDrug-naive schizophrenic patientsMetabolic side effectsPlasma lipid concentrationsAbnormal fat depositionAdverse metabolic sequelaeMIF concentrationsOlanzapine monotherapyMetabolic sequelaeOlanzapine administrationIntracerebroventricular injectionMIF antibodyFood intakeClinical utilitySchizophrenic patientsSide effects
2014
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN, investigators I. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial. American Heart Journal 2014, 168: 823-829.e6. PMID: 25458644, PMCID: PMC4254508, DOI: 10.1016/j.ahj.2014.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognition DisordersDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansHypoglycemic AgentsInsulin ResistanceIschemic Attack, TransientMaleMiddle AgedMyocardial InfarctionPatient Outcome AssessmentPioglitazoneRisk AssessmentRisk FactorsSecondary PreventionStrokeSurvival AnalysisThiazolidinedionesConceptsTransient ischemic attackMyocardial infarctionIschemic attackVascular eventsIschemic strokeSecondary preventionIRIS trialInsulin resistanceHomeostasis model assessment-insulin resistanceModel assessment-insulin resistanceEffectiveness of pioglitazoneInsulin Resistance InterventionRecent ischemic strokeRecurrent vascular eventsAssessment-insulin resistanceIschemic vascular eventsAcute coronary syndromeInsulin-resistant patientsInsulin-sensitizing drugsEligible patientsIndex strokeNondiabetic patientsCardiovascular outcomesCause mortalityCoronary syndrome
2009
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal Of Medical Genetics 2009, 48: 73. PMID: 19553198, DOI: 10.1136/jmg.2009.069013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsStructured consensus processGuideline processDiagnosis of HHTGuidelines Working GroupLife-threatening hemorrhageHealth care workersHereditary haemorrhagic telangiectasiaOvid MEDLINE databasesConsensus processSignificant arteriovenous malformationsAutosomal dominant diseaseSymptomatic diseaseSystematic search strategyWorking GroupConsensus guidelinesArteriovenous malformationsEvidence tablesClinic staffGuideline conferenceHealth care administratorsGastrointestinal tractAvailable screeningCare workersGuideline methodologistsMEDLINE database
2006
Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging
Papaioannou GI, Kasapis C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. Journal Of Nuclear Cardiology 2006, 13: 362-368. PMID: 16750781, DOI: 10.1016/j.nuclcard.2006.01.022.Peer-Reviewed Original ResearchConceptsEndothelium-dependent vasodilationEndothelium-independent vasodilationCoronary artery diseaseMyocardial perfusion imagingRelative myocardial ischemiaAsymptomatic patientsEndothelial functionNegative predictive valueMyocardial ischemiaAsymptomatic type 2 diabetic patientsExclusion of CADPredictive valueAdenosine myocardial perfusion imagingPeripheral vascular endothelial functionType 2 diabetic patientsType 2 diabetes mellitusHigh negative predictive valueAsymptomatic Diabetics (DIAD) studyBrachial artery ultrasonographyVascular endothelial functionDetection of ischemiaEDV responseRelative ischemiaEndothelial dysfunctionOvert atherosclerosis
2001
Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patients
Russell R, Chyun D, Song S, Sherwin R, Tamborlane W, Lee F, Pfeifer M, Rife F, Wackers F, Young L. Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patients. AJP Endocrinology And Metabolism 2001, 281: e1029-e1036. PMID: 11595660, DOI: 10.1152/ajpendo.2001.281.5.e1029.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiac OutputCatecholaminesChemical PrecipitationDiabetes Mellitus, Type 1DiastoleEpinephrineFatty Acids, NonesterifiedFemaleGlucagonGlucose Clamp TechniqueHeartHeart RateHumansHydrocortisoneHypoglycemiaInsulinLactic AcidMaleNorepinephrinePolyethylene GlycolsStroke VolumeSystoleVentricular Function, LeftConceptsType 1 diabetic patientsInsulin-induced hypoglycemiaNondiabetic groupType 1 diabetesDiabetic subjectsEuglycemic hyperinsulinemiaDiabetic patientsNondiabetic subjectsCardiac responseLeft ventricular systolicHealthy nondiabetic subjectsEquilibrium radionuclide angiographyDiabetic groupDiastolic functionVentricular systolicCardiovascular consequencesVentricular functionBlunted increaseCardiac outputGlucagon concentrationsPlasma catecholaminesRadionuclide angiographyInsulin infusionEuglycemic conditionsHypoglycemia
2000
Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia
Garcia-Tsao G, Korzenik J, Young L, Henderson K, Jain D, Byrd B, Pollak J, White R. Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal Of Medicine 2000, 343: 931-936. PMID: 11006369, DOI: 10.1056/nejm200009283431305.Peer-Reviewed Original ResearchConceptsHereditary hemorrhagic telangiectasiaHigh-output heart failureHemorrhagic telangiectasiaHeart failureMedian periodPortal hypertensionLiver involvementClinical findingsBiliary diseasePulmonary capillary wedge pressureElevated alkaline phosphatase levelsHepatic sinusoidal pressureSymptomatic liver involvementTypical clinical presentationAlkaline phosphatase levelsAutosomal dominant disorderHyperdynamic circulationAngiodysplastic lesionsCardiac indexLiver transplantationVariceal bleedingWedge pressureMedical therapyRendu-OslerClinical presentation